PE-backed Antengene trades flat after $359m HK IPO
Antengene, a China-based drug developer that previously raised $238 million across three private funding rounds, closed roughly flat on its first day of trading in Hong Kong following a HK$2.78 billion ($359 million) IPO.
The company sold 154.1 million shares for HK$18.08 apiece, the top end of the indicative range, according to a filing. Ten cornerstone investors, including Fidelity, GIC Private, BlackRock, Boyu Capital,...
More on Greater China
Latest News
Carlyle faces activist challenge to Japan Asia Group deal
An investment firm with ties to renowned Japanese activist investor Yoshiaki Murakami is challenging The Carlyle Group’s JPY37 ($355 million) bid for Japan Asia Group by launching a tender offer of its own.
Hong Kong regulation: Carry on
The proposal to place a 0% tax on carried interest has been welcomed in Hong Kong, but PE industry participants are quietly looking to Hong Kong Monetary Authority to ensure balanced execution of the policy
Fund focus: Oceanpine opens to external capital
Technology and healthcare-focused Oceanpine Capital sees the large GP commitment to its fund and the network of its founder as key differentiators in a competitive Chinese market
CPE, SDIC lead $46m round for China's Jaka Robotics
Chinese industrial robot manufacturer Jaka Robotics has raised RMB300m ($46m) in Series C funding led by CPE and State Development and Investment Corporation (SDIC).